Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817531 | 1.00 | PPARA (0.53) | PPARAPPARGITGB3ITGA2BHDAC8 | |
| SCHEMBL6813874 | 1.00 | PPARA (0.53) | PPARAPPARGITGB3ITGA2BHDAC8 | |
| SCHEMBL6818140 | 0.87 | PPARA (0.51) | PPARAPPARGITGB3ITGA2BHDAC8 | |
| SCHEMBL6818144 | 0.87 | PPARA (0.51) | PPARAPPARGITGB3ITGA2BHDAC8 | |
| SCHEMBL6817490 | 0.87 | PPARA (0.51) | PPARAPPARGITGB3ITGA2BHDAC8 | |
| SCHEMBL6818110 | 0.87 | PPARA (0.49) | PPARAPPARGITGB3ITGA2BHDAC8 | |
| SCHEMBL6921681 | 0.87 | PPARA (0.54) | PPARAPPARGITGB3ITGA2BHDAC8 | |
| SCHEMBL601719 | 0.86 | PPARG (0.72) | PPARAPPARGITGB3ITGA2B | |
| SCHEMBL5393093 | 0.86 | PPARG (0.72) | PPARAPPARGITGB3ITGA2B | |
| SCHEMBL5388906 | 0.85 | PPARA (0.60) | PPARAPPARGITGB3ITGA2BHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | claimed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | claimed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | PPARA 74/4885PPARG 47/4885ITGB3 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.